Androgen Deprivation Therapy Associated With A Significant Risk Of De Novo Diabetes Mellitus And Worsening Glycemic Control In Diabetic Patients

Main Category: Urology / Nephrology
Also Included In: Prostate / Prostate Cancer;  Diabetes
Article Date: 25 May 2006 - 0:00 PDT

email to a friend   printer friendly   view / write opinions
UroToday.com - Abstract 128: While androgen deprivation therapy for prostate cancer is known to result in poor glycemic control, the exact risk of de novo diabetes mellitus has not well defined.

Furthermore, screening and prevention strategies for patients starting on ADT have not been established.

Kincade and colleagues from Memphis reviewed their experience with 394 patients who received ADT either with LHRH agonists or orchiectomy. The risk of de novo diabetes mellitus was 11.4%, which was significantly greater in patients with a history of obesity.

Furthermore, in patients with pre-existing diabetes mellitus, worsening glycemic control (> 5% increase in HbA1c) developed in 42% percent of patients. Vitamin D supplementation was found to be associated with a protective effect.

Prostate cancer: Epidemiology and Natural History (I) Sunday May 21, 2006

By Ricardo Sánchez-Ortiz, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to:
http://www.urotoday.com

Copyright © 2006 - UroToday